The REAC-TAVI Trial: Is There a Need for More Potent Antithrombotic Strategy in TAVR?
JACC Cardiovasc Interv
.
2019 Apr 22;12(8):802-803.
doi: 10.1016/j.jcin.2019.02.004.
Authors
Amin Polzin
,
Verena Veulemans
,
Lisa Dannenberg
,
Malte Kelm
,
Tobias Zeus
PMID:
31000021
DOI:
10.1016/j.jcin.2019.02.004
No abstract available
Publication types
Letter
Comment
MeSH terms
Aortic Valve / surgery
Aortic Valve Stenosis / surgery*
Fibrinolytic Agents
Humans
Transcatheter Aortic Valve Replacement*
Treatment Outcome
Substances
Fibrinolytic Agents